Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00303186
Status:
COMPLETED
Last Update Posted:
2012-07-30
First Post:
2006-03-14
Brief Title:
Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
An Observational Study to Evaluate the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the directindirect costs of disease management in patients with refractory psoriatic arthritis PsA Primary outcomes are to qualify the economic burden of refractory PsA care The secondary outcomes are to assess efficacy safety and cost effectiveness of different therapies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B1801109 | None | None | None |